You are here

Our Company

Cancer Research Technology (CRT) is dedicated to advancing discoveries to beat cancer by developing and commercialising exciting new discoveries in cancer research. We’re the meeting point between academia and industry. Our deep understanding of both perspectives enables us to translate promising research into commercial propositions to deliver patient benefit and commercial value that will support further cancer research.

We’re uniquely placed to capitalise on the research and connections of our parent organisation Cancer Research UK, the world’s largest charitable funder of cancer research, and the strong links we’ve established with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide.


  • We have exclusive rights to £350 million of cancer research per year.
  • Last year we leveraged £16 million in industry funding to progress promising cancer research.
  • Cancer Research UK’s world-class scientists have contributed to over 20,000 academic publications to date.
  • Our portfolio contains over 200 projects available for licensing and co-development.
  • A proven track record of successful innovation stems from 30 years’ specialist experience in the commercialisation of cancer research.
  • We currently have more than 30 partnered agents in pre-clinical and clinical development, and 5 drugs already on the market and benefiting patients.
  • To date, CRT-DL has established 6 major industry partnerships with AstraZeneca, Teva, FORMA, Merck, MRCT and Artios.
  • We have 1 focus: CANCER.

 
  • CRT INC.

    CRT is based in the UK but we’re not just UK focused. We also operate CRT Inc., a US subsidiary, which forms an extension of our Business Development team. CRT Inc. is based in Cambridge, Massachusetts; a major hub for life-science organisations and a centre of academic excellence. Dr Andrea Schievella, President of CRT Inc., has been focussed on partnering early stage life sciences technologies for over 15 years.  

  • CRT-DL

    CRT-DL (CRT Discovery Laboratories) is the in-house drug discovery unit of Cancer Research Technology based at the Babraham Research Campus, Cambridge, and the London Bioscience Innovation Centre. Our expertise spans cancer target validation and disease positioning, assay development and high throughput screening, protein crystallography, medicinal chemistry, PK-PD and cancer models.

    CRT-DL has an exclusive focus on establishing and prosecuting biologically-themed multi-project alliances with industry.  We bring together the best minds in basic and clinical cancer research, the rigour and drive of pharmaceutical and biotech companies, and our in-house drug discovery and alliance management capabilities to deliver breakthrough medicines for cancer patients.
     

    Visit the CRT DL website

  • RESEARCH TOOLS

    CRT offers a reagent commercialisation service for products such as mono and polyclonal antibodies, mice, cell lines, small molecules and other tools. We have exclusive access to reagents emanating from CRUK funded research but our product portfolio is not just oncology focused: we offer reagents with applications in a number of fields of use. Our reagent portfolio is the largest single source of UK academic antibodies. In October 2014 CRT launched Ximbio, an online portal for the life science community to exchange knowledge and trade reagents. Developed to change the way that research reagents are searched, sourced and shared, Ximbio aims to broaden the range of tools available to scientists globally, supporting and advancing life science research.

  • CDP

    CDP (Clinical Development Partnerships) is an innovative initiative launched by Cancer Research UK and CRT to bring new life to promising therapies that have been de-prioritised by pharmaceutical and biotech companies. CDP puts shelved projects back into clinical development. Early phase clinical development is carried out at no initial cost to the company and then on a shared risk/reward basis, enabling pharmas to maximise the value of their pipeline and potentially develop new treatments for patients.

CRT INC. Open

CRT is based in the UK but we’re not just UK focused. We also operate CRT Inc., a US subsidiary, which forms an extension of our Business Development team. CRT Inc. is based in Cambridge, Massachusetts; a major hub for life-science organisations and a centre of academic excellence. Dr Andrea Schievella, President of CRT Inc., has been focussed on partnering early stage life sciences technologies for over 15 years.  

Related links

CRT-DL Open

CRT-DL (CRT Discovery Laboratories) is the in-house drug discovery unit of Cancer Research Technology based at the Babraham Research Campus, Cambridge, and the London Bioscience Innovation Centre. Our expertise spans cancer target validation and disease positioning, assay development and high throughput screening, protein crystallography, medicinal chemistry, PK-PD and cancer models.

CRT-DL has an exclusive focus on establishing and prosecuting biologically-themed multi-project alliances with industry.  We bring together the best minds in basic and clinical cancer research, the rigour and drive of pharmaceutical and biotech companies, and our in-house drug discovery and alliance management capabilities to deliver breakthrough medicines for cancer patients.
 

Visit the CRT DL website

Related links

RESEARCH TOOLS Open

CRT offers a reagent commercialisation service for products such as mono and polyclonal antibodies, mice, cell lines, small molecules and other tools. We have exclusive access to reagents emanating from CRUK funded research but our product portfolio is not just oncology focused: we offer reagents with applications in a number of fields of use. Our reagent portfolio is the largest single source of UK academic antibodies. In October 2014 CRT launched Ximbio, an online portal for the life science community to exchange knowledge and trade reagents. Developed to change the way that research reagents are searched, sourced and shared, Ximbio aims to broaden the range of tools available to scientists globally, supporting and advancing life science research.

Related links

CDP Open

CDP (Clinical Development Partnerships) is an innovative initiative launched by Cancer Research UK and CRT to bring new life to promising therapies that have been de-prioritised by pharmaceutical and biotech companies. CDP puts shelved projects back into clinical development. Early phase clinical development is carried out at no initial cost to the company and then on a shared risk/reward basis, enabling pharmas to maximise the value of their pipeline and potentially develop new treatments for patients.

Related links